Your browser is no longer supported. Please, upgrade your browser.
Settings
HJLI Hancock Jaffe Laboratories, Inc. daily Stock Chart
HJLI [NASD]
Hancock Jaffe Laboratories, Inc.
Index- P/E- EPS (ttm)-1.55 Insider Own50.14% Shs Outstand10.43M Perf Week37.93%
Market Cap25.03M Forward P/E- EPS next Y- Insider Trans- Shs Float5.84M Perf Month54.84%
Income-17.80M PEG- EPS next Q- Inst Own1.80% Short Float1.36% Perf Quarter50.94%
Sales0.30M P/S83.44 EPS this Y- Inst Trans349.78% Short Ratio0.55 Perf Half Y0.00%
Book/sh0.17 P/B14.12 EPS next Y- ROA- Target Price- Perf Year-
Cash/sh0.26 P/C9.27 EPS next 5Y- ROE- 52W Range1.31 - 5.64 Perf YTD62.71%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-57.45% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin70.40% 52W Low83.21% ATR0.29
Employees9 Current Ratio- Sales Q/Q-82.60% Oper. Margin- RSI (14)81.42 Volatility30.58% 14.99%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.63 Prev Close2.39
ShortableYes LT Debt/Eq0.00 EarningsMar 20 Payout- Avg Volume143.37K Price2.40
Recom- SMA2050.28% SMA5050.12% SMA2001.50% Volume90,640 Change0.42%
Mar-18-19 08:31AM  Hancock Jaffe Announces Successful Start to CoreoGraft Study at Texas Heart Institute ACCESSWIRE
Mar-14-19 02:30PM  These Four Healthcare Stocks Could Test March Highs ACCESSWIRE +20.11%
Mar-13-19 08:55AM  Hancock Jaffe Completes $2.7 Million Private Placement of Common Stock ACCESSWIRE +16.00%
Feb-19-19 08:31AM  Hancock Jaffe Successfully Starts First-in-Human VenoValve Study GlobeNewswire
Jan-28-19 08:00AM  Hancock Jaffe Announces Objectives for Upcoming CoreoGraft Study GlobeNewswire
Jan-15-19 08:00AM  Dr. Marc H. Glickman to Present at 6th Israeli Vascular Access Conference GlobeNewswire
Jan-09-19 08:00AM  Hancock Jaffe Announces End Points for First-in-Human VenoValve Study GlobeNewswire
Dec-17-18 08:00AM  Hancock Jaffe Receives Approval for First-in-Human VenoValve Study GlobeNewswire -7.56%
Dec-04-18 08:00AM  Hancock Jaffe Announces January CoreoGraft Study at the Texas Heart Institute GlobeNewswire
Nov-20-18 08:00AM  Hancock Jaffe Updates Status of Application to INVIMA for First-In-Human VenoValve Trial in Colombia GlobeNewswire -5.64%
Nov-13-18 09:30AM  Hancock Jaffe Appoints Chris Sarner as Vice President of Regulatory Affairs and Quality Assurance GlobeNewswire -12.50%
Oct-09-18 06:00AM  Hancock Jaffe Enters into Sponsored Research Agreement for CoreoGraft with World-Renowned Texas Heart Institute GlobeNewswire -7.24%
Oct-02-18 06:00AM  Hancock Jaffe Appoints Three New Independent Directors GlobeNewswire -11.38%
Sep-28-18 06:00AM  Hancock Jaffe Laboratories to Present at The MicroCap Conference on October 2, 2018 in New York City GlobeNewswire
Sep-26-18 03:11PM  What Investors Should Know About Hancock Jaffe Laboratories Incs (NASDAQ:HJLI) Financial Strength Simply Wall St. -6.57%
Sep-24-18 06:00AM  Hancock Jaffe Submits Application to INVIMA for First-In-Human VenoValve Trial in Colombia GlobeNewswire
Sep-20-18 09:30AM  Diamond Equity Research Initiates Coverage on Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI) with a Valuation of $6.60 Per Share GlobeNewswire +13.00%
06:00AM  Hancock Jaffe to Present at Fourth Annual Robins Equity Research Roundup Conference GlobeNewswire
Sep-17-18 06:00AM  New Study Confirms Significant Potential U.S. Market for Hancock Jaffes VenoValve® GlobeNewswire +6.90%
Sep-12-18 06:00AM  Hancock Jaffe Laboratories VenoValve Featured in Journal of Vascular Surgery Venous and Lymphatic Disorders as a Future Option for Treating Deep Vein Disease GlobeNewswire
Aug-09-18 07:00AM  Hancock Jaffe Laboratories Receives Medical Research Committee Approval for First-in-Human VenoValve Study GlobeNewswire
Jul-24-18 07:00AM  Hancock Jaffe Laboratories Receives Ethics Committee Approval for First-in-Human VenoValve Study GlobeNewswire -5.16%
Jul-13-18 06:18PM  Hancock Jaffe Appoints Bob Rankin as Chief Financial Officer GlobeNewswire
Jul-11-18 08:00AM  Hancock Jaffe Laboratories to Conduct Analysis for FDA Submission Package for Bioprosthetic Heart Valve GlobeNewswire
Jun-20-18 08:00AM  Hancock Jaffe Laboratories Selects Site for First-in-Human VenoValve Study GlobeNewswire
Jun-12-18 02:40PM  Hancock Jaffe Laboratories, Inc. Announces Full Exercise of $1,125,000 Underwriters Over Allotment GlobeNewswire -5.84%
Jun-05-18 01:19PM  Hancock Jaffe Laboratories, Inc. Announces Closing of $7.5 Million Initial Public Offering GlobeNewswire
09:47AM  Hancock Jaffe Laboratories (HJLI) Stock: A Flagship Product That Should Not Be Ignored! ACCESSWIRE
May-31-18 07:30AM  Hancock Jaffe Laboratories, Inc. Announces Pricing of Initial Public Offering GlobeNewswire
Hancock Jaffe Laboratories, Inc., a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease. Its products include the Bioprosthetic Heart Valve, a bio-prosthetic heart valve designed to mimic and function like a native heart valve; the CoreoGraft, a device for use as an alternate or supplemental coronary vascular conduit in coronary bypass surgery; and the Venous Valve, a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency. The company was founded in 1987 and is headquartered in Irvine, California. As of July 18, 2006, Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.